{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:37:01Z","timestamp":1792445821588,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,8]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>IL-6 levels in bone marrow predict event-free survival in pediatric AML. Exogenous IL-6 protects AML blasts from chemotherapy-induced apoptosis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017007856","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:40:19Z","timestamp":1501634419000},"page":"1387-1397","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance"],"prefix":"10.1182","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2464","authenticated-orcid":false,"given":"Alexandra M.","family":"Stevens","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime O.","family":"Munoz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos S.","family":"Gaikwad","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-3703","authenticated-orcid":false,"given":"Michele S.","family":"Redell","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"issue":"27","key":"2019111607180918500_B1","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111607180918500_B2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"16","key":"2019111607180918500_B3","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111607180918500_B4","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/blood-2013-01-476614","article-title":"Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children\u2019s Oncology Group","volume":"121","author":"Sung","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111607180918500_B5","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2019111607180918500_B6","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","article-title":"Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98","volume":"28","author":"von Neuhoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111607180918500_B7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.V116.21.761.761","article-title":"Conventional cytogenetics, molecular profiling, and flow cytometric response data allow the creation of a two-tiered risk-group system for risk-based therapy allocation in childhood AML: a report from the Children\u2019s Oncology Group","volume":"116","author":"Alonzo","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111607180918500_B8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pbc.22612","article-title":"Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study","volume":"55","author":"Gorman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2019111607180918500_B9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.24432","article-title":"Children\u2019s Oncology Group\u2019s 2013 blueprint for research: acute myeloid leukemia","volume":"60","author":"Gamis","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2019111607180918500_B10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","article-title":"Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels","volume":"61","author":"Sanchez-Correa","year":"2013","journal-title":"Cytokine"},{"issue":"8","key":"2019111607180918500_B11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/cas.12459","article-title":"Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia","volume":"105","author":"Han","year":"2014","journal-title":"Cancer Sci"},{"issue":"5","key":"2019111607180918500_B12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jped.2014.12.004","article-title":"Comparison of biochemical and immunological profile of pediatric patients with acute myeloid leukemia in relation to healthy individuals","volume":"91","author":"Sanches","year":"2015","journal-title":"J Pediatr (Rio J)"},{"issue":"7","key":"2019111607180918500_B13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2012-04-421925","article-title":"FACS analysis of Stat3\/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children\u2019s Oncology Group report","volume":"121","author":"Redell","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111607180918500_B14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"issue":"2","key":"2019111607180918500_B15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jcp.10364","article-title":"STAT proteins: from normal control of cellular events to tumorigenesis","volume":"197","author":"Cal\u00f2","year":"2003","journal-title":"J Cell Physiol"},{"key":"2019111607180918500_B16","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1038\/bcj.2013.63","article-title":"A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases","volume":"3","author":"Hayakawa","year":"2013","journal-title":"Blood Cancer J"},{"issue":"21","key":"2019111607180918500_B17","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/sj.onc.1203486","article-title":"STAT signaling in the pathogenesis and treatment of leukemias","volume":"19","author":"Lin","year":"2000","journal-title":"Oncogene"},{"issue":"21","key":"2019111607180918500_B18","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","article-title":"Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor","volume":"117","author":"Redell","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111607180918500_B19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.V99.1.252","article-title":"Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival","volume":"99","author":"Benekli","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2019111607180918500_B20","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.3324\/haematol.2015.131508","article-title":"Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"100","author":"Stevens","year":"2015","journal-title":"Haematologica"},{"issue":"22","key":"2019111607180918500_B21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.899.899","article-title":"The addition of bortezomib to standard chemotherapy for pediatric acute myeloid leukemia has increased toxicity without therapeutic benefit: a report from the Children\u2019s Oncology Group","volume":"128","author":"Aplenc","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111607180918500_B22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V128.22.1211.1211","article-title":"Prognostic significance of 11q23\/MLL fusion partners in children with acute myeloid leukemia (AML): results from the Children\u2019s Oncology Group (COG) trial AAML0531","volume":"128","author":"Guest","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111607180918500_B23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.12852","article-title":"Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children\u2019s Oncology Group","volume":"166","author":"Tarlock","year":"2014","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111607180918500_B24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/00365518709168934","article-title":"Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological diseases","volume":"47","author":"Koistinen","year":"1987","journal-title":"Scand J Clin Lab Invest"},{"issue":"A3.B","key":"2019111607180918500_B25","first-page":"1","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2001","journal-title":"Curr Protoc Immunol"},{"issue":"15","key":"2019111607180918500_B26","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","article-title":"A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia","volume":"119","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"2019111607180918500_B27","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.349","article-title":"Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells","author":"Yan","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2019111607180918500_B28","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bjh.13492","article-title":"Stromal CYR61 confers resistance to mitoxantrone via spleen tyrosine kinase activation in human acute myeloid leukaemia","volume":"170","author":"Long","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111607180918500_B29","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","article-title":"Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas","volume":"117","author":"Gao","year":"2007","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111607180918500_B30","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2015.145","article-title":"Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow","volume":"29","author":"Matthes","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111607180918500_B31","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1172\/JCI32533","article-title":"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland","volume":"117","author":"Sansone","year":"2007","journal-title":"J Clin Invest"},{"issue":"12","key":"2019111607180918500_B32","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood.V95.12.3765","article-title":"Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6","volume":"95","author":"Schuringa","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2019111607180918500_B33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.scr.2015.09.008","article-title":"The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells","volume":"15","author":"Reikvam","year":"2015","journal-title":"Stem Cell Res (Amst)"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/18\/1387\/878389\/advances007856.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/18\/1387\/878389\/advances007856.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T01:30:43Z","timestamp":1602639043000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/18\/1387\/15669\/Interleukin6-levels-predict-eventfree-survival-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017007856","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}